. . . "Jur\u010Dek, Tom\u00E1\u0161" . "Dvo\u0159\u00E1kov\u00E1, Dana" . . "RIV/00216224:14110/09:00036369" . . "13" . "CEBPA Gene mutational status A complete screening using high-resolution melt curve analysis" . . . . . "6"^^ . "CEBPA Gene mutational status A complete screening using high-resolution melt curve analysis"@en . "K\u0159\u00EDstkov\u00E1, Zlatu\u0161e" . "Mayer, Ji\u0159\u00ED" . "306192" . . . "Je\u017E\u00ED\u0161kov\u00E1, Ivana" . . . . "RIV/00216224:14110/09:00036369!RIV11-MSM-14110___" . "3" . "In recent years, several independent prognostic factors in cytogenetically normal acute myeloid leukemia (CN-AML) have been reported. Mutations or the expression levels of certatin genes have been often used as molecular markers for preidiction of a patients outcome or for evaluation of treatment outcome. One of them, the gene encoding CCAAT/enhanced binding protein alpha (CEBPA), plays an important role in myeloid differentiation and, whn mutated, confers a favorable prognosis for patients with CN-AML. Complete mutation screening of the CEBPA gene is therefore beneficial and requires fast, precise, and sensitive diagnostic tools. Thus, for routine diagnostics, we developed a screening method using high-resolution melt curve analysis prior to direct sequencing, where only positive samples (according to reference) are further sequenced." . "acute myeloid leukemia; CEBPA mutation"@en . "CEBPA Gene mutational status A complete screening using high-resolution melt curve analysis" . "000269290600004" . "4"^^ . "1177-1062" . . "In recent years, several independent prognostic factors in cytogenetically normal acute myeloid leukemia (CN-AML) have been reported. Mutations or the expression levels of certatin genes have been often used as molecular markers for preidiction of a patients outcome or for evaluation of treatment outcome. One of them, the gene encoding CCAAT/enhanced binding protein alpha (CEBPA), plays an important role in myeloid differentiation and, whn mutated, confers a favorable prognosis for patients with CN-AML. Complete mutation screening of the CEBPA gene is therefore beneficial and requires fast, precise, and sensitive diagnostic tools. Thus, for routine diagnostics, we developed a screening method using high-resolution melt curve analysis prior to direct sequencing, where only positive samples (according to reference) are further sequenced."@en . "CZ - \u010Cesk\u00E1 republika" . "[EAB069696207]" . . "CEBPA Gene mutational status A complete screening using high-resolution melt curve analysis"@en . "R\u00E1zga, Filip" . "6"^^ . "V, Z(MSM0021622430)" . . "14110" . . "Molecular diagnosis and therapy" .